Geron (NASDAQ:GERN) Now Covered by TD Cowen

Analysts at TD Cowen initiated coverage on shares of Geron (NASDAQ:GERN – Get Free Report) in a report released on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $10.00 price target on the biopharmaceutical company’s stock. TD Cowen’s price objective points to a potential upside of 154.45% from the company’s current price. […]

Leave a Reply

Your email address will not be published.

Previous post SVB Leerink Initiates Coverage on Immunocore (NASDAQ:IMCR)
Next post FirstCash (NASDAQ:FCFS) Rating Increased to Buy at Loop Capital